Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ryvu Therapeutics stock price, quote, forecast and news

RVU.WA
PLSELVT00013
A1JUH2

Price

53.10 PLN
Today +/-
+0.26 PLN
Today %
+2.09 %
P

Ryvu Therapeutics stock price

PLN
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ryvu Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ryvu Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ryvu Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ryvu Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ryvu Therapeutics Stock Price History

DateRyvu Therapeutics Price
8/22/202453.10 PLN
8/21/202452.00 PLN
8/20/202452.60 PLN
8/19/202454.00 PLN
8/16/202453.50 PLN
8/14/202453.00 PLN
8/13/202453.20 PLN
8/12/202452.80 PLN
8/9/202451.90 PLN
8/8/202451.40 PLN
8/7/202451.10 PLN
8/6/202449.70 PLN
8/5/202448.90 PLN
8/2/202453.40 PLN
8/1/202453.60 PLN
7/31/202451.10 PLN
7/30/202452.00 PLN
7/29/202453.00 PLN
7/26/202452.50 PLN
7/25/202449.60 PLN

Ryvu Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ryvu Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ryvu Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ryvu Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ryvu Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ryvu Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ryvu Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ryvu Therapeutics’s growth potential.

Ryvu Therapeutics Revenue, EBIT and net profit per share

DateRyvu Therapeutics RevenueRyvu Therapeutics EBITRyvu Therapeutics Net Income
2026e265.77 M PLN26.01 M PLN-22,754.26 PLN
2025e272.4 M PLN-72.87 M PLN-72.86 M PLN
2024e184.48 M PLN-92.72 M PLN-90.6 M PLN
202346.86 M PLN-97.38 M PLN-92.11 M PLN
202238.95 M PLN-70.69 M PLN-83.78 M PLN
202111.19 M PLN-78.89 M PLN-79.08 M PLN
202015.65 M PLN-35.67 M PLN-31.69 M PLN
20193.8 M PLN-45.39 M PLN285.64 M PLN
201877.21 M PLN-13.62 M PLN-106,320 PLN
201767.54 M PLN12.66 M PLN6.41 M PLN
201648.13 M PLN-1.22 M PLN2.72 M PLN
201541.03 M PLN2.07 M PLN6.27 M PLN
201428.86 M PLN5.27 M PLN5.85 M PLN
201313.05 M PLN-2.23 M PLN-2.45 M PLN
20129.51 M PLN-6.12 M PLN-5.55 M PLN

Ryvu Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M PLN)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M PLN)EBIT (M PLN)EBIT MARGIN (%)NET INCOME (M PLN)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e
9132841486777315113846184272265
-44.44115.3846.4317.0739.5814.93-96.10400.00-26.67245.4521.05300.0047.83-2.57
11.1123.0850.0070.7370.8361.1966.23-300.0040.00-227.27-43.48---
131429344151-96-25020000
-6-252-112-13-45-35-78-70-97-92-7226
-66.67-15.3817.864.88-2.0817.91-16.88-1,500.00-233.33-709.09-184.21-210.87-50.00-26.479.81
-5-256260285-31-79-83-92-90-720
--60.00-350.0020.00-66.67200.00---110.88154.845.0610.84-2.17-20.00-
10.4610.4610.4613.0513.7413.7715.5215.9716.7718.3618.3622.9000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Ryvu Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ryvu Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M PLN)RECEIVABLES (M PLN)OTHER REC. (M PLN)INVENTORIES (M PLN)OTHER CURRENT LIAB. (M PLN)CURRENT ASSETS (M PLN)TANGIBLE ASSETS (M PLN)LONG-T. INVEST. (M PLN)LONG-T. REC. (M PLN)INTANGIBLE ASSETS (M PLN)GOODWILL (k PLN)OTHER NON-CURRENT ASSETS (M PLN)NON-CURRENT ASSETS (M PLN)TOTAL ASSETS (M PLN)LIABILITIESCOMMON STOCK (M PLN)ADDITIONAL PAID-IN CAPITAL (M PLN)RETAINED EARNINGS (M PLN)OTHER EQUITY (k PLN)UNREAL. GAINS/LOSSES (M PLN)EQUITY (M PLN)LIABILITIES (M PLN)PROVISIONS (M PLN)OTHER SHORT-TERM LIAB. (M PLN)SHORT-TERM DEBTS (M PLN)LONG-TERM DEBT PORTION (M PLN)SHORT-TERM REC. (M PLN)LONG-T. LIAB. (M PLN)DEFERRED TAXES (M PLN)OTHER LIAB. (M PLN)LONG-T. LIABILITIES (M PLN)DEBT (M PLN)TOTAL CAPITAL (M PLN)
201220132014201520162017201820192020202120222023
5.204.928.8129.0936.12110.3772.11161.1988.23345.41233.67
1.20713.0810.431014.371.792.25.941.059.19
1.803.34.885.959.764413.395.755.815.8923.65
0.400.71.171.41.591.991.591.681.961.762.12
0.201.40.580.792.392.491.111.552.323.839.77
8.8017.348.5247.6759.87173.2289.98172.36104.25367.93278.39
5.406.88.621.8331.3852.4466.1991.1691.1882.2277.56
0.20003.122.0422.8323.7529.1229.420.4823.44
0000000005.8258.850
000.11.996.362.362.42.922.323.044.286.34
3000300280.74280.74280.74280.7400000
1.902.35.859.867.654.530.790.680.930.0817.48
7.809.516.7241.4543.782.4893.65123.28130.37365.9124.81
16.6026.865.2489.12103.57255.7183.63295.64234.61733.83403.2
4.204.25.255.385.516.396.397.347.347.349.25
00025.2825.4825.48154.7145.19279.06279.06279.06519.75
1.705.115.9224.5631.230.61289.98258.29195.87377.9665.99
000-2.62-42.63110.07211.73-320,977.45-320,977.45-320,977-320,979-335,395
000000000000
5.909.346.4555.3762.3191.91120.58223.72161.3343.39259.59
1.905.43.916.799.3716.3621.6110.8614.1914.4525.35
1.500.72.453.941.512.643.415.314.8611.712.22
4.108.89.676.414.0613.132.314.5614.4116.7731.59
000000000000
0.200.50.31.81.823.433.33.082.751.90.54
7.7015.416.3218.9326.7535.5730.6233.8136.244.8169.7
0.300.20.37.826.1710.045.924.332.320.879.22
0.100.10.170.210.534.575.146.040.4400
2.5021.576.446.1310.6621.3727.7428.5685.9164.69
2.902.32.0414.4812.8325.2732.4338.1131.3186.7773.91
10.6017.718.3633.4139.5860.8463.0571.9267.51131.59143.61
16.502764.8188.78101.88252.75183.63295.64228.81474.98403.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ryvu Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ryvu Therapeutics's financial health and stability.

Assets

Ryvu Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ryvu Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ryvu Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ryvu Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M PLN)DEPRECIATION (M PLN)DEFERRED TAXES (M PLN)CHANGES IN WORKING CAPITAL (M PLN)NON-CASH ITEM (M PLN)PAID INTEREST (M PLN)PAID TAXES (M PLN)NET CASH FLOW FROM OPERATING ACTIVITIES (M PLN)CAPITAL EXPENDITURES (M PLN)CASH FLOW FROM INVESTING ACTIVITIES (M PLN)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M PLN)INTEREST INCOME AND EXPENSES (M PLN)NET DEBT CHANGE (M PLN)NET CHANGE IN EQUITY (M PLN)CASH FLOW FROM FINANCING ACTIVITIES (M PLN)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M PLN)TOTAL DIVIDENDS PAID (M PLN)NET CHANGE IN CASH FLOW (M PLN)FREE CASH FLOW (M PLN)SHARE-BASED COMPENSATION (M PLN)
201220132014201520162017201820192020202120222023
-5-256260285-31-79-83-92
1223358712121210
000000000-500
-5-6-13-25-13-2-312013-961-14
000011-14-331-5223110
000000000000
000000000050
-9-7-4-16-610-36-17-10-5821-84
-2-2-3-5-21-21-23-23-34-11-9-201
-2-2-3-4-18-21-37-2-5580-195
000020-1321-212095
000000000000
00004-2-2-2-3-3-2-1
0002700134014300-7
997452417147-2130-2-2240
998181918160-800250
000000000000
-200240774-2264-5218-43
-11.59-9.37-8.51-21.62-27.49-10.58-59.86-41.4-44.82-70.8712.03-285.74
000000000000

Ryvu Therapeutics stock margins

The Ryvu Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ryvu Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ryvu Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ryvu Therapeutics's sales revenue. A higher gross margin percentage indicates that the Ryvu Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ryvu Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ryvu Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ryvu Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ryvu Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ryvu Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ryvu Therapeutics Margin History

Ryvu Therapeutics Gross marginRyvu Therapeutics Profit marginRyvu Therapeutics EBIT marginRyvu Therapeutics Profit margin
2026e44.8 %9.79 %-0.01 %
2025e44.8 %-26.75 %-26.75 %
2024e44.8 %-50.26 %-49.11 %
202344.8 %-207.8 %-196.57 %
2022-1.65 %-181.5 %-215.12 %
2021-228.3 %-705.21 %-706.94 %
202044 %-227.92 %-202.47 %
2019-237.09 %-1,194.87 %7,520.15 %
201867.15 %-17.64 %-0.14 %
201761.61 %18.75 %9.49 %
201672.26 %-2.54 %5.65 %
201571.79 %5.05 %15.28 %
201451.06 %18.26 %20.27 %
201328.2 %-17.09 %-18.77 %
201212.93 %-64.35 %-58.36 %

Ryvu Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Ryvu Therapeutics earnings per share therefore indicates how much revenue Ryvu Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ryvu Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ryvu Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ryvu Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ryvu Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ryvu Therapeutics Revenue, EBIT and net profit per share

DateRyvu Therapeutics Sales per ShareRyvu Therapeutics EBIT per shareRyvu Therapeutics Earnings per Share
2026e11.5 PLN0 PLN-0 PLN
2025e11.78 PLN0 PLN-3.15 PLN
2024e7.98 PLN0 PLN-3.92 PLN
20232.05 PLN-4.25 PLN-4.02 PLN
20222.12 PLN-3.85 PLN-4.56 PLN
20210.61 PLN-4.3 PLN-4.31 PLN
20200.93 PLN-2.13 PLN-1.89 PLN
20190.24 PLN-2.84 PLN17.88 PLN
20184.97 PLN-0.88 PLN-0.01 PLN
20174.9 PLN0.92 PLN0.47 PLN
20163.5 PLN-0.09 PLN0.2 PLN
20153.14 PLN0.16 PLN0.48 PLN
20142.76 PLN0.5 PLN0.56 PLN
20131.25 PLN-0.21 PLN-0.23 PLN
20120.91 PLN-0.59 PLN-0.53 PLN

Ryvu Therapeutics business model

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.com.

Ryvu Therapeutics SWOT Analysis

Strengths

Ryvu Therapeutics SA has a strong portfolio of innovative therapies and drugs.

The company has a highly skilled and experienced management team.

Ryvu Therapeutics SA has established partnerships with renowned research institutions.

Weaknesses

The company is dependent on the success of its drug development pipeline.

Ryvu Therapeutics SA is a relatively small player in the pharmaceutical industry.

The company may face challenges in securing sufficient funding for its research and development activities.

Opportunities

There is a growing demand for effective and personalized treatments in the healthcare market.

Ryvu Therapeutics SA can leverage advancements in technology to enhance its drug discovery process.

The company can explore expansion into new geographical markets.

Threats

The pharmaceutical industry is highly competitive and subject to stringent regulatory requirements.

Ryvu Therapeutics SA may face challenges in obtaining intellectual property protection for its innovations.

Unexpected clinical trial outcomes or failures could negatively impact the company's reputation and financial stability.

Ryvu Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ryvu Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Ryvu Therapeutics shares outstanding

The number of shares was Ryvu Therapeutics in 2023 — This indicates how many shares 22.898 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ryvu Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ryvu Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ryvu Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ryvu Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Ryvu Therapeutics.

Ryvu Therapeutics list of shareholders

%
Name
Stocks
Change
Date
8.29 % BioNTech SE1,917,43702/22/2024
8.22 % Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA1,900,00002/22/2024
5.94 % FORUM Towarzystwo Funduszy Inwestycyjnych S.A.1,372,713011/2/2023
5.94 % Wesolowski (Tadeusz)1,372,7131,372,7132/22/2024
3.57 % Sieczkowski (Boguslaw Stanislaw)825,34802/22/2024
2.06 % Norges Bank Investment Management (NBIM)476,148112,45012/31/2023
17.48 % Towarzystwo Funduszy Inwestycyjnych Allianz Polska SA4,042,23602/22/2024
17.45 % Przewiezlikowski (Pawel)4,033,286-31,7502/22/2024
0.63 % ESALIENS TFI SA146,76230,7816/30/2023
0.62 % UNIQA Towarzystwo Funduszy Inwestycyjnych S. A142,52425,6376/30/2023
1
2

Ryvu Therapeutics Executives and Management Board

Mr. Vatnak Vat-ho
Ryvu Therapeutics Chief Business Officer, Member of the Management Board
Compensation 937,984 PLN
Dr. Krzysztof Brzozka
Ryvu Therapeutics Vice President of the Management Board, Chief Scientific Officer
Compensation 595,507 PLN
Dr. Kamil Sitarz
Ryvu Therapeutics Chief Operating Officer, Member of the Management Board
Compensation 485,541 PLN
Mr. Pawel Przewiezlikowski50
Ryvu Therapeutics President of the Management Board
Compensation 341,388 PLN
Dr. Piotr Romanowski
Ryvu Therapeutics Independent Chairman of the Supervisory Board (since 2010)
Compensation 150,477 PLN
1
2
3

Most common questions regarding Ryvu Therapeutics

What values and corporate philosophy does Ryvu Therapeutics represent?

Ryvu Therapeutics SA is a biotechnology company that is committed to transforming patient care and addressing unmet medical needs. The company's corporate philosophy revolves around innovation, scientific excellence, and a patient-centric approach. Ryvu Therapeutics SA values the power of collaboration and partnerships, aiming to drive advancements in the field of oncology and rare diseases. With a focus on research and development, Ryvu Therapeutics SA strives to bring novel therapies to the market that have the potential to significantly improve and extend the lives of patients. This dedication to scientific discovery and a result-driven mindset defines the core values of Ryvu Therapeutics SA.

In which countries and regions is Ryvu Therapeutics primarily present?

Ryvu Therapeutics SA is primarily present in Poland, where it is headquartered.

What significant milestones has the company Ryvu Therapeutics achieved?

Ryvu Therapeutics SA has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2019, raising funds to support its research and development efforts. In October 2019, Ryvu Therapeutics SA entered into a collaboration agreement with an international pharmaceutical company for the development of innovative cancer therapies. Another noteworthy achievement is the advancement of its internal pipeline, particularly the progress made in the clinical development of its investigational drug candidates. These achievements demonstrate Ryvu Therapeutics SA's commitment to advancing novel therapies and establishing strategic partnerships in the field of oncology.

What is the history and background of the company Ryvu Therapeutics?

Ryvu Therapeutics SA is a biopharmaceutical company founded in 2007 in Poland. It focuses on discovering and developing innovative small molecule therapies for the treatment of various cancers. Ryvu Therapeutics SA has a strong research and development pipeline, with a particular emphasis on targeted therapies that can potentially address the underlying mechanisms driving cancer growth. The company has made significant progress in preclinical and early clinical stages, with several promising drug candidates. Ryvu Therapeutics SA aims to improve patient outcomes and contribute to the advancement of cancer treatment through its dedication to scientific excellence and innovative drug development approaches.

Who are the main competitors of Ryvu Therapeutics in the market?

The main competitors of Ryvu Therapeutics SA in the market include Genmab A/S, Incyte Corporation, and Gilead Sciences, Inc. These companies are also active in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. However, Ryvu Therapeutics SA brings unique offerings to the market with its portfolio of proprietary drug candidates and therapeutic platforms. With its commitment to advancing precision oncology and targeted therapies, Ryvu Therapeutics SA distinguishes itself from its competitors and aims to make a significant impact in the field of biopharmaceuticals.

In which industries is Ryvu Therapeutics primarily active?

Ryvu Therapeutics SA is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Ryvu Therapeutics?

Ryvu Therapeutics SA operates under a business model focused on developing innovative therapies to address unmet medical needs. They specialize in research and development of novel small molecule drugs targeting cancer and inflammatory diseases. As a biopharmaceutical company, Ryvu Therapeutics is dedicated to discovering and advancing potential treatments through rigorous scientific methods. By leveraging their expertise in drug discovery and understanding of disease biology, they strive to deliver breakthrough medicines that can improve patient outcomes. Ryvu Therapeutics aims to bring innovative therapies to market that have the potential to transform patient care in areas where medical needs are not yet met.

What is the P/E ratio of Ryvu Therapeutics 2024?

The Ryvu Therapeutics P/E ratio is -13.42.

What is the P/S ratio of Ryvu Therapeutics 2024?

The Ryvu Therapeutics P/S ratio is 6.59.

What is the AlleAktien quality score of Ryvu Therapeutics?

The AlleAktien quality score for Ryvu Therapeutics is 6/10.

What is the revenue of Ryvu Therapeutics 2024?

The expected Ryvu Therapeutics revenue is 184.48 M PLN.

How high is the profit of Ryvu Therapeutics 2024?

The expected Ryvu Therapeutics profit is -90.6 M PLN.

What is the business model of Ryvu Therapeutics

Ryvu Therapeutics SA is a research-driven biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. The company collaborates closely with researchers and academics to make breakthrough discoveries in oncology research and translate them into clinical applications. The business model of Ryvu Therapeutics SA is based on combining innovative research with numerous partnerships with academic institutions to develop novel drugs that can be used against cancer and inflammatory diseases. The company's goal is to improve the lives of cancer patients and expand the boundaries of medicine through the development of innovative technologies and new treatment options. To achieve this, the company has a wide range of products in the pipeline, including small molecule inhibitors, biologics, and immunotherapies. In addition to developing new treatment options, Ryvu Therapeutics SA also works closely with academic institutions to make new discoveries in oncology research and translate them into clinical applications. The company aims to attract new partners and investors to expand its business model and venture into new therapy areas. Overall, Ryvu Therapeutics SA's business model offers a wide range of products and services tailored to the needs of cancer patients. The company combines innovative research with numerous partnerships with academic institutions to make groundbreaking discoveries in oncology research and translate them into clinical applications. With a wide range of products in the pipeline and a dedicated leadership team, Ryvu Therapeutics SA is well positioned to improve the lives of cancer patients and promote the growth of the company.

What is the Ryvu Therapeutics dividend?

Ryvu Therapeutics pays a dividend of 0 PLN distributed over payouts per year.

How often does Ryvu Therapeutics pay dividends?

The dividend cannot currently be calculated for Ryvu Therapeutics or the company does not pay out a dividend.

What is the Ryvu Therapeutics ISIN?

The ISIN of Ryvu Therapeutics is PLSELVT00013.

What is the Ryvu Therapeutics WKN?

The WKN of Ryvu Therapeutics is A1JUH2.

What is the Ryvu Therapeutics ticker?

The ticker of Ryvu Therapeutics is RVU.WA.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 8/24/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.

All fundamentals about Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.